Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Accutane/Generics Risk Program Should Include Mandatory Follow-Up Survey

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA advisory committee suggests  enhancements to Roche's SMART program to better prevent pregnancies. The proposal calls for a shared brand/generic system for patient registration.

You may also be interested in...



Enhanced Isotretinoin Risk Management Plan To Commence In Mid-2005

The program will include central registry for patients, prescribers and dispensing pharmacies, an FDA "Talk Paper" says. Celgene licenses patents covering Thalomid STEPS risk management program to isotretinoin manufacturers.

Enhanced Isotretinoin Risk Management Plan To Commence In Mid-2005

The program will include central registry for patients, prescribers and dispensing pharmacies, an FDA "Talk Paper" says. Celgene licenses patents covering Thalomid STEPS risk management program to isotretinoin manufacturers.

Ventiv Dermatology Sales Force To Promote Ranbaxy’s Isotretinoin

The firms sign multi-year agreement to market Sotret. Ventiv says it has established a specialty dermatology sales force to promote the product.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS058718

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel